Resverlogix Corp.

Resverlogix Corp.

August 14, 2006 09:30 ET

Resverlogix Corp. Expands CVD Franchise to NexVas'TM' VI: Novel Compounds Inhibiting and Protecting from "Vascular Inflammation"

CALGARY, ALBERTA--(CCNMatthews - Aug. 14, 2006) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it has expanded its Cardiovascular Disease (CVD) research efforts focused on vascular inflammation (VI). "Preliminary findings demonstrated that NexVas™ compounds have inhibitory effects on a number of inflammation markers comparable to and better than our positive control, a chemical entity representative of Atherogenics Inc's vascular inflammatory drug (AGI-1067) currently in pivotal phase 3 clinical studies (ARISE)," stated Donald J. McCaffrey, President and CEO of Resverlogix. "Currently, our compounds are early in development and have not yet surpassed the AGI-1067 control in potency. However, having successfully increased the potency of our NexVas PR compounds, we are confident in our ability to improve potency with ongoing chemistry efforts and mining of our patent estate," McCaffrey added.

"Expanding upon our vast NexVas™ technology platform into vascular inflammation will continue to position Resverlogix as a leader in the management of plaque stabilization and atherosclerosis, the major underlying cause of cardiovascular disease" added Dr. Johansson.

In 1998 the American Heart Association established a special advisory board panel to identify novel targets for CVD risk. One of the key findings from this panel was that markers of inflammation were one class of emerging targets. Resverlogix believes that this research expansion will continue to position the company as a leader in CVD while presenting multiple commercial opportunities.

About Resverlogix

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR), is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company's second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company's secondary focus is TGF-ß Shield™, a program that aims to address the unmet medical need of grievous diseases, such as cancer and fibrosis, with a TGF- ß inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Kenneth E. Lebioda
    Vice President Business & Market Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Resverlogix Corp.
    Theresa Kennedy
    Vice President Corporate Communications
    (604) 538-7072
    (403) 256-8495 (FAX)